Menopause, heart and bone health: prevention, risk and the role of HRT

Does HRT protect the heart and bones in the same way?

No. HRT can reduce bone loss and fractures in studied settings, but it is not a general prescription for cardiovascular prevention. NICE advises against offering either combined or estrogen-only HRT for primary or secondary prevention of cardiovascular disease. A decision about treating hot flashes, a decision about fracture prevention and a decision about managing blood pressure or cholesterol are related conversations with different evidence and goals. [1], [2], [5]

Bone care also needs more than a universal “take hormones” rule. Age, previous fractures, bone density, falls, other medicines and the broader risk-benefit balance affect the choice. UK NOGG guidance and the Canadian osteoporosis guideline allow a role for HRT in selected circumstances; their recommendations are not identical or a license for every product. [2], [3]

The useful starting point is your actual risk and purpose: bothersome menopause symptoms, a low-trauma fracture, established osteoporosis, cardiovascular risk factors or a combination. You can pursue menopause symptom relief while keeping ordinary heart and bone prevention in place. HRT does not replace a clinically indicated blood-pressure medicine, statin or osteoporosis treatment. [1], [3], [5]

Which question are you trying to answer?

A risk calculation helps organize a discussion; it is not a guarantee that an event will or will not happen. Ask which country-specific tool and clinical context apply. Previous disease, a fracture or certain secondary causes can change the pathway, rather than simply adding another number to routine screening. [3], [4], [5]

What do we know about fractures?

Randomized evidence supports a fracture benefit from the historical oral regimens studied in WHI. The combined CEE-plus-MPA trial and the separate CEE-only trial after hysterectomy both reported fewer hip fractures, alongside other benefits and harms. Those were specific populations and formulations, not trials of every current estrogen patch or progestogen combination. A real skeletal benefit does not make the complete risk profile identical for every treatment. [6], [7]

The current public Cochrane review summary and abstract describe long-term randomized evidence dominated by WHI and another older trial, with most participants postmenopausal and many over 60. It reports fracture reduction while retaining uncertainty and oral-regimen limitations. Its evidence search ended in September 2024. It does not establish one universally best contemporary product or answer every question in younger women and medically induced menopause. [11]

Bone mineral density is useful, but preventing a clinical fracture is the outcome that matters most. Changes in a scan and changes in fracture probability are related, not interchangeable. Falls, age and other clinical factors can affect risk even when a scan does not cross a familiar threshold. An individual before-and-after scan also cannot isolate the effect of HRT if exercise, nutrition, another medicine or measurement conditions changed. [3], [4]

How do guidelines position HRT for bone health?

NOGG gives a conditional recommendation to consider HRT as a first-line option for younger postmenopausal women aged 60 or under with high fracture risk and low baseline risk of adverse malignant and thromboembolic events. Continued use after 60 calls for individual risk-benefit discussion. “Conditional” and the qualifying risks matter; this is not a recommendation for every symptom-free person or every age. [2]

The Canadian 2023 guideline approaches medication choice through fracture risk and generally recommends bisphosphonates for people meeting its treatment criteria. It suggests menopausal hormone therapy as an alternative for females younger than 60 or within ten years after menopause who prioritize relief of substantial menopause symptoms. That is a different framing from simply choosing HRT because a scan is low. The guideline also discusses other options according to risk, suitability and preference. [3]

These positions should be identified by name rather than flattened into a worldwide rule. A product can also have a narrower licensed indication than a clinical guideline's discussion. Ask whether the proposed treatment addresses symptoms, fracture prevention or both, why it suits your risk profile, and how progress will be reviewed. Do not substitute a patch for a bone medicine or combine treatments because an online account sounds similar. [2], [3]

When is a bone-density scan useful?

DXA measures bone mineral density at specified sites. Its interpretation sits with age, fracture history and other risk factors; it is not a menopause hormone test. The US USPSTF 2025 recommendation supports screening women aged 65 or over and younger postmenopausal women at increased risk after clinical risk assessment. This routine-screening recommendation does not apply to people already known to have osteoporosis or a fragility-fracture history, or to certain secondary causes. [4]

The Canadian 2023 guideline uses a targeted approach in postmenopausal females and males aged 50 or over. Its original algorithm identifies assessment groups including ages 65–69 with a risk factor, age 70 or over without risk factors, and ages 50–64 with a previous qualifying fracture or at least two risk factors. The fracture definition and clinical context matter. These criteria are not a promise that a scan is publicly covered everywhere or a reason to postpone assessment of a new fracture. [3]

Younger people, premature ovarian insufficiency, early menopause and secondary bone loss need their own consideration. Tell the clinician about previous low-trauma fractures, long-term glucocorticoid use, falls and other relevant conditions. If a scan is proposed, ask what decision it will change and which repeat interval is suitable. Neither guideline makes “every menopausal person every two years” the universal rule. [1], [3], [4]

Why is the timing hypothesis not a heart-prevention prescription?

Age and time since menopause matter to the overall HRT risk-benefit discussion. NAMS 2022 describes a generally favorable balance for treating bothersome vasomotor symptoms and preventing bone loss in people younger than 60 or within ten years of menopause, without contraindications. This is a purpose-specific statement; it is not a demonstration that HRT should be prescribed to everyone to prevent heart attacks. [9]

ELITE randomized early and late postmenopausal groups to a specific estradiol intervention or placebo. It found a different effect on progression of carotid intima-media thickness according to timing, while cardiac CT measures did not show corresponding treatment differences. A vascular surrogate is not the same outcome as a prevented heart attack or stroke. Its research regimen is not a prescribing calendar copied into this guide. [8]

Observational findings can add information, especially for contemporary routes, while remaining vulnerable to differences between people who choose or receive treatment. Neither a plausible mechanism nor an association proves clinical-event prevention. Current NICE recommendations therefore keep symptom treatment separate from cardiovascular prevention. The WHI guide explains why later analyses refine the historical trials without retracting them. [1], [6], [7], [8]

What if you already have cardiovascular disease?

A history of coronary heart disease or stroke needs specialist discussion of symptom-treatment options and the named product's restrictions. NICE says HRT should be discussed and offered, if appropriate, by a professional with menopause expertise in this setting. It does not say everyone with such a history can safely start any HRT or that HRT should replace secondary-prevention medicines. [1]

The VA/DoD August 2026 guideline likewise separates prevention from symptom treatment. Its recommendation against oral menopausal estrogen solely for primary stroke prevention is strong; its recommendation against oral estrogen solely for cardiovascular prevention is weak. A separate weak recommendation considers systemic estradiol for bothersome vasomotor symptoms in selected people with established cardiovascular disease who are both younger than 60 and within ten years of menopause. [10]

Those qualifications must stay attached. The VA/DoD selected-disease condition uses “and”; it is not the same as applying NAMS's general “or” timing description. A weak guideline statement does not override a label contraindication or establish safety for every cardiovascular diagnosis. Specialist care and the actual clinical context remain necessary. [1], [9], [10]

What prevention matters whether or not you use HRT?

For cardiovascular health, discuss blood pressure, lipids, smoking, diabetes and relevant history with your clinician. NICE's cardiovascular guideline includes clinical risk assessment, lifestyle support and lipid-lowering treatment when indicated. A healthier-looking cholesterol value after a hormone change is not proof that cardiovascular events will be prevented or that another medicine is no longer needed. [5]

For bones, ask about exercise suited to your fracture risk, falls, nutrition and whether osteoporosis treatment is indicated. The Canadian guideline includes balance and functional training, progressive resistance exercise and nutrition as parts of care. These are valuable alongside appropriate medicines, not a guarantee that activity or supplements alone reverse established osteoporosis. A clinician or appropriately trained exercise professional can adapt activities when a fracture or other limitation changes what is safe. [3]

Make the plan feasible. A short walk that you can sustain, smoking support that you can access or a medication schedule you understand is more useful than an ideal routine you cannot follow. Discuss barriers such as pain, caregiving, cost or transportation. These practical suggestions are editorial preparation, not a personalized exercise or nutrition prescription.

Urgent symptoms belong outside routine prevention: suspected heart-attack symptoms or sudden face, arm or speech changes suggesting stroke require emergency help. Do not assume chest symptoms or a new neurological problem are menopause, anxiety or a side effect that can wait for your next review. Use local emergency services; the NHS sources describe UK numbers, not a worldwide telephone number. [12], [13]

What happens to bone care when HRT stops?

Revisit fracture risk and the original treatment purpose. NOGG recommends reassessing fracture risk when HRT is discontinued and considering an alternative when indicated. That is not a claim that every person needs another medicine immediately or that the benefit persists unchanged indefinitely. If HRT served both symptom and skeletal purposes, the stopping discussion should address both. [2]

Other bone medicines have different continuity rules. NOGG and the Canadian guideline warn against unplanned denosumab discontinuation because vertebral-fracture risk can increase and an alternative plan may be needed. That is a drug-specific issue; do not copy a “drug holiday” from a different osteoporosis treatment or assume all bone medicines can be stopped alike. This guide does not construct a replacement regimen. [2], [3]

Ask who manages the transition, whether a scan or other assessment is needed and what follow-up will check. Keep symptom recurrence and fracture prevention as distinct questions. See the stopping guide for the menopause discussion, while following the osteoporosis team's actual instructions.

What do public discussions contribute?

A September 2026 Mumsnet discussion asks whether low bone density justifies HRT when typical menopause symptoms are minimal. A June 2026 osteoporosis discussion describes uncertainty about starting later, competing treatment choices, perceived benefit and experiences in which HRT did not suit. These questions are useful because the reason for treatment is often more complicated than “heart and bones.” [14], [15]

The selected accounts are not comparative evidence or a way to predict response. No usernames, personal scan values, doses or instructions to reject osteoporosis medicines are reproduced. Claims that WHI was erased, that patches remove all clot risk or that a scan guarantees reimbursement are not adopted. A good clinical question is which outcome and guideline actually apply to the person asking. [14], [15]

What should you bring to a prevention review?

Bring a concise medication list, previous scan reports, fracture history and the goals of your menopause treatment. Note a recent fall or fracture, a medicine change and barriers to taking treatment as prescribed. Ask whether cardiovascular and bone assessments need different follow-up. A symptom diary can show how you feel; it cannot diagnose osteoporosis or calculate future cardiovascular risk.

At review, useful questions include: which risk factors can change, why this medicine was chosen, what a repeat test will alter and what happens if treatment stops. If different clinicians manage menopause and osteoporosis, ask who owns the continuity plan. Practical record-keeping suggestions here are editorial and do not claim automatic clinical monitoring or risk calculation by a tracking app.

What questions are worth asking?

Should everyone take HRT to prevent heart disease?

No. NICE advises against HRT for primary or secondary cardiovascular prevention. A favorable balance for symptom treatment near menopause is a different statement, and vascular-surrogate or observational findings do not establish prevention for everyone. Review ordinary cardiovascular risks and indicated treatment whether or not you choose HRT. If you already have coronary disease or stroke, discuss symptoms with a professional who can assess that history and product restrictions. See timing and cardiovascular history. [1], [5], [8]

Can HRT be an osteoporosis treatment option?

Yes, in selected guideline-supported circumstances, but it is not the automatic choice for every patient. NOGG's conditional recommendation includes younger postmenopausal women with high fracture risk and low baseline malignant and thromboembolic risk. The Canadian guideline frames it as an alternative in selected younger or recently menopausal females prioritizing substantial symptom relief. Ask which recommendation and product indication support your plan, alongside the other bone options. See bone options. [2], [3]

Does osteopenia mean I should immediately start hormones?

A scan label alone is not the complete decision. Fracture history, age, falls, secondary causes, the relevant risk assessment and treatment goals also matter. A clinician can explain whether monitoring, changes in prevention or medication are appropriate in your situation. Hormones are one possible option in selected circumstances, with their own benefits and harms; another person's scan and prescription cannot determine yours. See screening and bone options for the assessment and guideline distinctions. [2], [3], [4]

Is the bone scan age the same in Canada and the US?

The cited guidelines use different approaches. USPSTF recommends routine screening at 65 or over, with risk-based screening for younger postmenopausal women. The Canadian 2023 guideline uses age and risk factors, including assessment at 70 without risk factors and earlier in specified groups. Known fractures, secondary causes and younger-age conditions need their own assessment. These recommendations are not universal coverage promises or reasons to ignore a fracture. See screening for the populations and exceptions. [3], [4]

If a patch has less clot risk, does it protect my heart?

A route-related risk comparison and cardiovascular prevention are different questions. NICE considers transdermal treatment in certain increased-VTE-risk situations, but that does not prove a patch prevents heart attacks or removes all vascular risk. The named medicine, your history and other risks still matter. Keep blood-pressure, lipid and diabetes care in place and discuss the treatment purpose. See timing and prevention, alongside the dedicated transdermal guide. [1], [5]

Can exercise and supplements replace an osteoporosis medicine?

Not automatically. Exercise, nutrition and falls prevention are parts of bone care, while a sufficiently high fracture risk can also call for pharmacotherapy. An active lifestyle or a supplement routine does not guarantee protection from fractures. Ask which activities suit your risk and whether diet or a supplement addresses an actual need. Review benefits, harms and preferences before declining or changing a prescribed medicine. See prevention and bone options. [3]

What happens to bone protection if I stop HRT?

Reassess the original purpose and fracture risk rather than assuming protection continues unchanged. NOGG recommends risk review and considering an alternative when indicated after stopping HRT. Not everyone needs the same next step. Other bone drugs have distinct stopping rules, especially denosumab, so do not copy a drug holiday or discontinue them without their own plan. Ask who coordinates the transition and what follow-up will check. See continuity and the linked stopping guide. [2], [3]

Can my symptom diary tell me whether my heart and bones are protected?

It can show symptom changes and help prepare a review, but it cannot diagnose osteoporosis or estimate cardiovascular protection. Bone care uses fracture history, appropriate scans and clinical risk assessment; cardiovascular prevention uses its own factors and treatment indications. Bring the records that inform each decision instead of treating a good week of sleep as evidence that long-term risks changed. See tracking, screening and prevention for a practical review plan. [3], [4], [5]

Glossary

Terms used in assessment and care.

Menopause

Usually identified after 12 months without a period when hormonal contraception does not explain the absence.

Postmenopause

The stage after menopause; symptoms can continue.

Estrogen

A hormone class that includes estradiol.

Estradiol

An estrogen made by the body and used in certain prescribed medicines.

Progesterone

A hormone and one member of the progestogen family.

Progestogen

A family of progesterone-like medicines; some provide uterine protection with estrogen.

Endometrium

The lining inside the uterus.

HRT / MHT

Hormone replacement therapy; menopausal hormone therapy in this guide.

Systemic treatment

Treatment reaching the wider body through the circulation.

Vasomotor symptoms

Hot flashes and night sweats.

Premature ovarian insufficiency

Loss or disturbance of ovarian activity before age 40, requiring its own assessment.

Hysterectomy

Surgical removal of the uterus; the extent of surgery matters.

Osteoporosis

A condition of skeletal fragility assessed through fractures, density and clinical context.

Osteopenia

A bone-density category below the reference range but above the usual osteoporosis threshold; not a full treatment decision.

DXA

Dual-energy X-ray absorptiometry, a method of measuring bone mineral density.

BMD

Bone mineral density; one factor in fracture-risk assessment.

T-score

Comparison of a bone-density result with a young-adult reference population.

Fragility fracture

A fracture after low trauma that requires clinical assessment and an appropriate prevention plan.

Fracture risk

Estimated probability of a fracture using a defined outcome, duration and clinical model.

FRAX

A fracture-risk assessment tool with country-specific models; not an HRT dose calculator.

Cardiovascular disease

Disease affecting the heart or blood vessels; the specific diagnosis matters.

Primary prevention

Trying to prevent a first disease event.

Secondary prevention

Preventing further events in someone with established disease.

VTE

Venous thromboembolism, including deep-vein thrombosis and pulmonary embolism.

Surrogate outcome

An intermediate measurement that does not itself establish prevention of a clinical event.

CIMT

Carotid intima-media thickness, a vascular measurement used in the ELITE trial.

Bisphosphonate

A class of osteoporosis medicines with specific indications and continuity rules.

Denosumab

An osteoporosis medicine that needs a planned approach if treatment is stopped.

Conditional recommendation

Guideline advice whose suitability depends on qualifications, evidence and preferences.

Screening

Assessment before a condition is already known; different from investigating a fracture.

How was this guide researched?

Source selection and limits

Current NICE menopause and cardiovascular recommendations, full NOGG pharmacological guidance and the original Canadian 2023 article/PDF were checked, including the Canadian assessment algorithm and selected MHT recommendation. USPSTF 2025 was read as US routine-screening guidance with exclusions. Original WHI and full ELITE provide bounded trial evidence; NAMS 2022 was accessible as the original PubMed abstract only. VA/DoD August 2026 relevant original clinical extraction was checked, not every appendix; prevention and weak selected-CVD symptom treatment remain separate. The full official public Cochrane summary/abstract, not its full review, displays November 27, 2025 and a September 2024 evidence cutoff despite a newer search-index date. Public discussions supply questions, not a treatment rule or personal risk estimate.

This is an AI-assisted Doserly editorial guide checked October 3, 2026. No independent clinician review is claimed. Doserly develops a commercial tracking app. Practical record-keeping suggestions are editorial advice, not a validated diagnostic scale or clinical-monitoring system. Material new guidance, labels or safety information trigger earlier source review.

Sources